Predix Pharmaceuticals

Predix Pharmaceuticals, established in 2003, was a biopharmaceutical company that concentrated on the discovery and development of small molecule drugs. The company's primary focus was on creating therapies for diseases that were inadequately treated by existing options, targeting a class of proteins known as G-protein coupled receptors (GPCRs). These receptors are crucial in a wide array of physiological processes, making them a significant target for drug development. The company's operations were centered around its proprietary computational drug design platform, which integrated structural biology, computational chemistry, and bioinformatics to predict the three-dimensional structure of GPCRs. This technology aimed to accelerate the drug discovery process, moving from a target to a drug candidate more efficiently than traditional methods.

The company's business model was rooted in leveraging this predictive science platform to build a pipeline of drug candidates. Predix Pharmaceuticals aimed to treat a variety of conditions, including central nervous system disorders, metabolic diseases like obesity, and pain. One of its notable achievements was advancing multiple product candidates into clinical and preclinical development. In a significant strategic move, Predix Pharmaceuticals merged with Epix Medical in 2006 to form a new entity named EPIX Pharmaceuticals. This merger combined Predix's drug discovery platform and pipeline with Epix's expertise in imaging agents, creating a more diversified biopharmaceutical company.

Keywords: biopharmaceutical, drug discovery, GPCRs, small molecule drugs, computational chemistry, structural biology, predictive science, central nervous system, metabolic diseases, preclinical development